XOSPATA® (gilteritinib) | Official Patient Site

Go to content

Main menu:

Xospata (gilteritinib) Patient Information - drugs.com

Interesting
XOSPATA® (gilteritinib) | Official Patient Site, Xospata (gilteritinib) Patient Information - drugs.com, Xospata (Gilteritinib Tablets): Side Effects, Interactions , XOSPATA® Tablets 40 mg - astellas.com, Astellas Pharma : Announces Approval in Japan for XOSPATA , Common Side Effects of Xospata (Gilteritinib Tablets) Drug , DailyMed - XOSPATA- gilteritinib tablet, Astellas Pharma Inc. : - Launch of XOSPATA Tablets 40 mg .
Heart rhythm problems (QT prolongation). XOSPATA may cause a heart problem called QT prolongation. Your healthcare provider should check the electrical activity of your heart with a test called electrocardiogram (ECG) before you start taking XOSPATA and during your treatment with XOSPATA. Tell your healthcare provider right away if you have a change in your heartbeat, or if you feel dizzy, lightheaded, or faint. The risk of QT prolongation is higher in people with low blood magnesium or low blood potassium levels. Your healthcare provider will do blood tests to check your potassium and magnesium levels before and during your treatment with XOSPATA.. Swallow XOSPATA tablets whole with a cup of water. XOSPATA can be taken with or without food. Do not break, crush or chew XOSPATA tablets. If you miss a dose of XOSPATA, take your dose as soon as possible on the same day at least 12 hours before your next scheduled dose. Return to your normal schedule the following day. Do not take 2 doses within 12 hours. What are the possible side effects of .
Xospata (gilteritinib) is a prescription medicine used to treat acute myeloid leukemia (AML) in adults with an abnormal FLT3 gene. Your doctor will test you for this gene.. XOSPATA (gilteritinib) is provided as a tablet for oral administration. Each tablet contains 40 mg of gilteritinib active ingredient as free base (corresponding to 44.2 mg gilteritinib fumarate). The inactive ingredients are mannitol, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, polyethylene glycol, titanium dioxide and ferric oxide.. XOSPATA® Tablets 40 mg Safety Data Sheet According To Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules And Regulations Date of issue: 11/29/2018. TOKYO, September 21, 2018 -Astellas Pharma Inc. today announced that XOSPATA® Tablets 40 mg , a FLT3 inhibitor received manufacturing and marketing approval for the treatment of | September 21, 2018. Xospata (gilteritinib) is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation as detected by an FDA-approved test.. XOSPATA (gilteritinib) is provided as a tablet for oral administration. Each tablet contains 40 mg of gilteritinib active ingredient as free base (corresponding to 44.2 mg gilteritinib fumarate). The inactive ingredients are mannitol, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, hypromellose, talc, polyethylene glycol, titanium dioxide and ferric oxide..
 
Copyright 2019. All rights reserved.
Back to content | Back to main menu